Increased expression of SRPK1 (serine/arginine-rich protein-specific kinase 1) is associated with progression and unfavorable prognosis in cervical squamous cell carcinoma

References

• Barth MJ. NCCN clinical practice guidelines in oncology (NCCN Guidelines (R))(vol 18, pg 1105, 2020). J National Compr Cancer Network. 2020;18(11):XLIV–XLIV.
   Web of Science ®Google Scholar
• Zheng Z, Yang X, Yao X, et al. Prognostic value of HPV 16/18 genotyping and geminin mRNA quantification in low-grade cervical squamous intraepithelial lesion. Bioengineered. 2021;12(2):11482–11489.
   PubMed Web of Science ®Google Scholar
• Huang ZY, Liao PJ, Liu YX, et al. Protein tyrosine phosphatase, receptor type B is a potential biomarker and facilitates cervical cancer metastasis via epithelial-mesenchymal transition. Bioengineered. 2021;12(1):5739–5748.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang J, Gao C, et al. Integral membrane protein 2A enhances sensitivity to chemotherapy via notch signaling pathway in cervical cancer. Bioengineered. 2021;12(2):10183–10193.
   PubMed Web of Science ®Google Scholar
• Lahue BJ, Baginska E, Li SS, et al. Health technology assessment on cervical cancer screening, 2000-2014. Int J Technol Assess Health Care. 2015;31(3):171–180.
   PubMed Web of Science ®Google Scholar
• Small W Jr., Bacon MA, Bajaj A, et al. Cervical cancer: a global health crisis. Cancer. 2017;123(13):2404–2412.
   PubMed Web of Science ®Google Scholar
• Bulk S, Visser O, Rozendaal L, et al. Incidence and survival rate of women with cervical cancer in the greater Amsterdam area. Br J Cancer. 2003;89(5):834–839.
   PubMed Web of Science ®Google Scholar
• Poolkerd S, Leelahakorn S, Manusirivithaya S, et al. Survival rate of recurrent cervical cancer patients. J Med Assoc Thai. 2006;89(3):275–282.
   PubMedGoogle Scholar
• Yoshida K, Kajiyama H, Utsumi F, et al. A post-recurrence survival-predicting indicator for cervical cancer from the analysis of 165 patients who developed recurrence. Mol Clin Oncol. 2018;8(2):281–285.
   PubMed Web of Science ®Google Scholar
• Oltean S, Bates DO. Hallmarks of alternative splicing in cancer. Oncogene. 2014;33(46):5311–5318.
   PubMed Web of Science ®Google Scholar
• Cerasuolo A, Buonaguro L, Buonaguro FM, et al. The role of RNA splicing factors in cancer: regulation of viral and human gene expression in human papillomavirus-related cervical cancer. Front Cell Dev Biol. 2020;8(474). DOI:10.3389/fcell.2020.00474
   PubMedGoogle Scholar
• Zhang YF, Wang YX, Zhang N, et al. Prognostic alternative splicing regulatory network of RBM25 in hepatocellular carcinoma. Bioengineered. 2021;12(1):1202–1211.
   PubMed Web of Science ®Google Scholar
• Corkery DP, Holly AC, Lahsaee S, et al. Connecting the speckles: splicing kinases and their role in tumorigenesis and treatment response. Nucleus (Austin, Tex). 2015;6(4):279–288.
   PubMed Web of Science ®Google Scholar
• Tang W, Wan S, Yang Z, et al. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics. 2018;34(3):398–406.
   PubMed Web of Science ®Google Scholar
• Wang Y, Wang F. Post-translational modifications of deubiquitinating enzymes: expanding the ubiquitin code. Front Pharmacol. 2021;12:1434.
   Web of Science ®Google Scholar
• Czubaty A, Piekiełko-Witkowska A. Protein kinases that phosphorylate splicing factors: roles in cancer development, progression and possible therapeutic options. Int J Biochem Cell Biol. 2017;91(Pt B):102–115.
   PubMedGoogle Scholar
• Gui JF, Tronchère H, Chandler SD, et al. Purification and characterization of a kinase specific for the serine- and arginine-rich pre-mRNA splicing factors. Proc Natl Acad Sci U S A. 1994;91(23):10824–10828.
   PubMed Web of Science ®Google Scholar
• Nikas IP, Themistocleous SC, Paschou SA, et al. Serine-Arginine protein kinase 1 (SRPK1) as a prognostic factor and potential therapeutic target in cancer: current evidence and future perspectives. Cells. 2019;9(1):19.
   PubMed Web of Science ®Google Scholar
• Liu H, Gong Z, Li K, et al. SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. J Exp Clin Cancer Res. 2021;40(1):1–16.
   PubMed Web of Science ®Google Scholar
• Hayes GM, Carrigan PE, Miller LJ. Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Res. 2007;67(5):2072–2080.
   PubMed Web of Science ®Google Scholar
• Bullock N, Potts J, Simpkin AJ, et al. Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. J Clin Pathol. 2016;69(2):171–175.
   PubMed Web of Science ®Google Scholar
• Zhou B, Li Y, Deng Q, et al. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Mol Cell Biochem. 2013;379(1–2):191–199.
   PubMed Web of Science ®Google Scholar
• Malvi P, Janostiak R, Chava S, et al. LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis. 2020;9(8):77.
   PubMed Web of Science ®Google Scholar
• Kurimchak AM, Kumar V, Herrera-Montávez C, et al. Kinome profiling of primary endometrial tumors using multiplexed inhibitor beads and mass spectrometry identifies SRPK1 as candidate therapeutic target. Mol Cell Proteomics. 2020;19(12):2068–2090.
   PubMed Web of Science ®Google Scholar
• Bullock N, Oltean S. The many faces of SRPK1. J Pathol. 2017;241(4):437–440.
   PubMed Web of Science ®Google Scholar
• Network CGAR. Albert Einstein college of medicine; Analytical biological services; Barretos cancer hospital. Baylor College of Medicine; Beckman Research Institute of City of Hope. Buck Institute for Research on Aging; 2017. p. 378–384.
   Google Scholar
• Tang Z, Li C, Kang B, et al. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102.
   PubMed Web of Science ®Google Scholar
• Liu H, Xu Y, Zhang Q, et al. Prognostic significance of TBL1XR1 in predicting liver metastasis for early stage colorectal cancer. Surg Oncol. 2017;26(1):13–20.
   PubMed Web of Science ®Google Scholar
• Chen T, Liu H, Liu Z, et al. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. Oncogene. 2021. DOI:10.1038/s41388-021-01850-1.
   Web of Science ®Google Scholar
• Lin JC, Lin CY, Tarn WY, et al. Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events. RNA. 2014;20(10):1621–1631.
   PubMed Web of Science ®Google Scholar
• Ren G, Sheng L, Liu H, et al. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Med Oncol. 2015;32(7):209.
   PubMed Web of Science ®Google Scholar
• Gong L, Song J, Lin X, et al. Serine-arginine protein kinase 1 promotes a cancer stem cell-like phenotype through activation of Wnt/β-catenin signalling in NSCLC. J Pathol. 2016;240(2):184–196.
   PubMed Web of Science ®Google Scholar
• Gammons MV, Lucas R, Dean R, et al. Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. Br J Cancer. 2014;111(3):477–485.
   PubMed Web of Science ®Google Scholar
• Wagner KD, Maï M E. Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’. Tumor Suppressor Wt1. 2019;8(1). DOI:10.3390/cells8010041
   Google Scholar
• Mavrou A, Oltean S. SRPK1 inhibition in prostate cancer: a novel anti-angiogenic treatment through modulation of VEGF alternative splicing. Pharmacol Res. 2016;107:276–281.
   PubMed Web of Science ®Google Scholar
• Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, et al. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol. 2006;29(1):225–235.
   PubMed Web of Science ®Google Scholar
• Huang JQ, Li HF, and Zhu J, et al. SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer. Journal of Translational Medicine. 2021;19(1):280.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Mhawech-Fauceglia P, Andrews C, et al. Elevated expression of the serine-arginine protein kinase 1 gene in ovarian cancer and its role in Cisplatin cytotoxicity in vitro. PloS one. 2012;7(12):e51030.
   PubMed Web of Science ®Google Scholar
• Siqueira RP, Barbosa Éde A, Polêto MD, et al. Potential antileukemia effect and structural analyses of SRPK Inhibition by N-(2-(Piperidin-1-yl)-5-(Trifluoromethyl)Phenyl)Isonicotinamide (SRPIN340). PloS one. 2015;10(8):e0134882.
   PubMed Web of Science ®Google Scholar
• Schenk PW, Stoop H, Bokemeyer C, et al. Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia (New York, NY). 2004;6(4):297–301.
   PubMed Web of Science ®Google Scholar
• Krishnakumar S, Mohan A, Kandalam M, et al. SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. Pediatr Blood Cancer. 2008;50(2):402–406.
   PubMed Web of Science ®Google Scholar
• Wang P, Zhou Z, Hu A, et al. Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Mol Cell. 2014;54(3):378–391.
   PubMed Web of Science ®Google Scholar
• Hatcher JM, Wu G, Zeng C, et al. SRPKIN-1: a covalent SRPK1/2 inhibitor that potently converts VEGF from Pro-angiogenic to Anti-angiogenic isoform. Cell Chem Biol. 2018;25(4):460–70.e6.
   PubMed Web of Science ®Google Scholar
• Chandra A, Ananda H, Singh N, et al. Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression. Aging (Albany NY). 2020;13(1):163–180.
   PubMedGoogle Scholar
• Wu F, Li J, Du X, et al. Chimeric antibody targeting SRPK-1 in the treatment of non-small cell lung cancer by inhibiting growth, migration and invasion. Mol Med Rep. 2017;16(2):2121–2127.
   PubMed Web of Science ®Google Scholar
• Gout S, Brambilla E, Boudria A, et al. Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PloS one. 2012;7(10):e46539.
   PubMed Web of Science ®Google Scholar
• Mole S, Faizo AAA, Hernandez-Lopez H, et al. Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis. J Gen Virol. 2020;101(5):523–532.
   PubMed Web of Science ®Google Scholar